China’s Groundbreaking Dual-Track Drug Reimbursement Reform Ushers in New Era for Pharma Market Access
Friday, November 14, 2025
China has reached a historic inflection point in healthcare reimbursement policy with the conclusion of negotiations for both the National Reimbursement Drug List (NRDL) and the first Commercial Health Insurance Innovative Drug List (CHIIDL), formalizing a dual-track payment model that aims to revolutionize market access for innovative medicines. The landmark policy, finalized in November 2025, represents the first time that an independent commercial insurance drug list has been introduced in tandem with the traditional national reimbursement channel. This transformative adjustment comes as China’s medical insurance system, administered by the National Healthcare Security Administration (NHSA), seeks to balance fiscal realities with accelerating demand for clinical innovation—a tension felt acutely by both domestic and global pharmaceutical enterprises seeking entry into the world’s second-largest drug market.
The conventional NRDL, which has undergone its eighth update since 2017, emphasizes broad population coverage and cost restrictions. High-cost, cutting-edge therapies—such as CAR-T cell products, oncology biologics, and orphan drugs—have historically struggled to secure NRDL listing due to stringent pricing thresholds and limited government health budgets. However, the new CHIIDL offers a differentiated pathway, permitting greater pricing leeway and tailored negotiation under a market-oriented framework. According to official NHSA releases and industry sources, 24 highly innovative products were under consideration for the CHIIDL in 2025, alongside 127 submissions for the NRDL. Notably, therapies with per-dose costs in excess of 1 million RMB, previously out of reach due to budget constraints, are on track for CHIIDL inclusion—signaling more accessible commercialization routes for multinational biopharma innovators.
The impact of this reform extends beyond listing mechanics: it institutes a multi-tier security model combining state-backed basic coverage and premium-funded commercial options. In 2024, basic government insurance covered 1.326 billion people with annual outlays of RMB 2.97 trillion, though average per capita contributions and funding remain modest. Meanwhile, commercial health insurance premiums swelled to RMB 977.3 billion, growing 8.2% year-over-year but still representing less than 10% of overall innovative drug spend. The advent of the CHIIDL is poised to spark further growth in commercial coverage and facilitate the inclusion of ultra-expensive drugs in clinical pathways, especially as pilot programs in cities like Shanghai and Shandong demonstrate seamless one-stop reimbursement that marries public and private insurance processes. Already, millions have benefited from cross-system payment platforms that reduce claims friction and improve patient access at the point of care.
For global pharmaceutical manufacturers, these structural reforms signal a profound recalibration of China’s international market access model. The dual-track system accelerates inclusion of novel medicines into major hospital formularies, leverages coordinated expert review, and enables parallel strategy development for regulatory, pricing, and commercial engagement. In turn, this offers a strategic blueprint to other emerging markets seeking to reconcile innovation incentives with universal health coverage—a dynamic increasingly observed in Southeast Asia, the Middle East, and parts of Latin America. Moreover, with the first official lists expected in December 2025 and nationwide implementation slated for January 2026, stakeholders are on alert for ripple effects in distribution, market entry, and cross-border partnership opportunities.
Despite the policy’s promise, challenges remain in terms of full-scale hospital adoption, harmonization of medical record platforms, and ensuring sustainability for commercial health plans underwriting high-cost drug risks. While inclusive health plans such as China’s “Hui Min Bao” have broadened the consumer base for commercial insurance, experts warn that absorbing ultra-premium therapies without corresponding premium adjustments could jeopardize insurer stability. Future success hinges on scaling employer group coverage, investing in long-term medical products, and navigating the “last mile” of inclusion from paper policy to bedside delivery. Internationally, China’s reform stands out as a model for hybrid healthcare financing—balancing government stewardship of basic coverage with market-driven expansion of innovative medicine access, and offering a roadmap for pharma executives, regulators, and investors seeking sustainable growth amid rising global demand for advanced therapeutics.
The dual-track era marks a paradigm shift in Asian pharma strategy, positioning China at the forefront of payment innovation and providing multinational drug companies with new levers for negotiation, portfolio planning, and real-world evidence generation. As further regulatory details and hospital adoption protocols emerge, the region—and the world—will closely watch to see whether this disruptive model can deliver on its bold promise of expanded innovation access without undermining affordability or financial sustainability.
